Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactulose + bisacodyl is a combination laxative therapy primarily used for the management of chronic constipation and for bowel preparation prior to diagnostic procedures such as colonoscopy. The combination utilizes two distinct mechanisms of action to facilitate bowel movements. Lactulose is a synthetic disaccharide that acts as an osmotic laxative; it is not absorbed in the small intestine and is fermented by colonic bacteria into organic acids (such as lactic and acetic acids), which increase osmotic pressure and acidify the colonic contents, thereby drawing water into the intestinal lumen. Bisacodyl is a stimulant laxative that acts directly on the colonic mucosa and the myenteric plexus to stimulate peristalsis and increase the secretion of water and electrolytes. This dual approach provides a synergistic effect, improving stool consistency and frequency more effectively than either agent alone in certain patient populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactulose + bisacodyl.